USD
+$0.00
(+0.00%
)At Close (As of Nov 5, 2025)
$6.61M
Market Cap
0.478
P/E Ratio
2.3
EPS
$2.93
52 Week High
$0.30
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $6.5M |
| Total Revenue | $9.8M |
| Cost Of Revenue | $3.3M |
| Costof Goods And Services Sold | $3.3M |
| Operating Income | -$5.8M |
| Selling General And Administrative | $7.4M |
| Research And Development | $42K |
| Operating Expenses | $12M |
| Investment Income Net | - |
| Net Interest Income | -$904K |
| Interest Income | $96K |
| Interest Expense | $904K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $381K |
| Income Before Tax | -$7.2M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$7.2M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$6.3M |
| Ebitda | -$5.9M |
| Net Income | -$7.2M |
| Field | Value (USD) |
|---|---|
| Total Assets | $3.4M |
| Total Current Assets | $1.9M |
| Cash And Cash Equivalents At Carrying Value | $430K |
| Cash And Short Term Investments | $430K |
| Inventory | $765K |
| Current Net Receivables | $389K |
| Total Non Current Assets | $1.5M |
| Property Plant Equipment | $1M |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | $351K |
| Other Non Current Assets | - |
| Total Liabilities | $3.6M |
| Total Current Liabilities | $2.8M |
| Current Accounts Payable | $623K |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $963K |
| Total Non Current Liabilities | $709K |
| Capital Lease Obligations | $1.1M |
| Long Term Debt | - |
| Current Long Term Debt | $565K |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $1.7M |
| Other Current Liabilities | $769K |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | -$129K |
| Treasury Stock | - |
| Retained Earnings | -$183M |
| Common Stock | $49K |
| Common Stock Shares Outstanding | $3.4M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$5.2M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $381K |
| Capital Expenditures | $6K |
| Change In Receivables | - |
| Change In Inventory | -$272K |
| Profit Loss | - |
| Cashflow From Investment | $1.1M |
| Cashflow From Financing | $1.5M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | $3.1M |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$7.1M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $6.5M |
| Total Revenue | $9.8M |
| Cost Of Revenue | $3.3M |
| Costof Goods And Services Sold | $3.3M |
| Operating Income | -$5.8M |
| Selling General And Administrative | $7.4M |
| Research And Development | $42K |
| Operating Expenses | $12M |
| Investment Income Net | - |
| Net Interest Income | -$904K |
| Interest Income | $96K |
| Interest Expense | $904K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $381K |
| Income Before Tax | -$7.2M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$7.2M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$6.3M |
| Ebitda | -$5.9M |
| Net Income | -$7.2M |
| Field | Value |
|---|---|
| Ex Dividend Date | 2025-09-30 |
| Declaration Date | 2025-08-26 |
| Record Date | 2025-09-15 |
| Payment Date | 2025-09-29 |
| Amount | 0.8 |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
NovaBay Pharmaceuticals Inc. (NBY) is a California-based medical device innovator specializing in advanced ocular health solutions. The company leverages proprietary technologies to develop therapeutics for eye infections and inflammation, addressing significant unmet clinical needs. With a commitment to improving patient outcomes and a strategic focus on the growing eye care market, NovaBay presents an appealing opportunity for institutional investors targeting the healthcare and medical device sectors.